Compare UiPath Inc (PATH) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Health Care Select Sector SPDR Fund — how do they compare? UiPath Inc trades at $13.49 (market cap $6.91B), while Health Care Select Sector SPDR Fund trades at $169.7 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 6.3× UiPath Inc's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| PATH | XLV | |
|---|---|---|
Market Cap | $6.91B | $43.48B |
Volume | 34,321,250 | 11,121,431 |
Sector | Technology | — |
52-Week High | $19.29 | $175.68 |
52-Week Low | $9.38 | $141.95 |
Typical Hold Time | 139 Days | 100 Days |
Enterprise Value | $5.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.07, down 0.23% with bearish technical signals despite strong fundamentals. The company shows improving financials with revenue growth from $1.43B in 2025 to projected $1.7B in 2026, transitioning to profitability with a 21.03% net margin. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though technical indicators show resistance at $13 with RSI suggesting mixed momentum.
PATH offers compelling value with a P/E of 19.78 and analyst consensus target of $15.13 (16% upside), but faces execution risks and competitive pressure. The stock's bearish technical setup contrasts with fundamental improvement, creating potential for volatility. Investors should weigh strong profitability metrics against recent price weakness and mixed analyst sentiment.
XLV trades at $169.58 with a slight 0.46% daily gain amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent news highlights XLV's competitive expense ratio of 0.08% and defensive healthcare sector positioning. Options activity shows increased put volume, suggesting some investor caution despite the fund's diversification across 61 healthcare stocks.
The healthcare ETF presents a cost-effective defensive play with potential upside if political volatility subsides post-elections. Key risks include sector-specific regulatory pressures and biotech trial failures impacting holdings. Current technical weakness near support at $166 requires monitoring for potential breakdown, though the fund's low fees and broad diversification provide stability during market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
